Dear Colleagues,

I am delighted to welcome you to the CARE-NMD International Conference on DMD on behalf of the project and organising committee. The EU-funded CARE-NMD project (2010-2013) has spent the last three years investigating care and quality of life for those living with DMD in Europe, and we will use this conference to discuss key findings from the project and other international research activities concerning care for DMD.

We have assembled an exciting programme of speakers over the next two days here in the beautiful city of Budapest. These are promising times in research into neuromuscular diseases such as DMD. The development of tailored therapeutic approaches that seek to address underlying pathology and modify disease progression give us real hope for the future.

However, there are also challenges. We must ensure that all patients and their families have access to the best possible care, both for its own sake and to ensure that clinical trials of new therapies can demonstrate efficacy. The consensus Standards of Care will need expansion to cover new areas of medicine and recent scientific and clinical advances. We must always consider how we can improve care, and align with the wider research picture and new developments in the field.

This conference therefore aims both to highlight current best practice in DMD care, and to explore opportunities for the future. With have consciously chosen a broad theme of “care for people living with DMD”, and our sessions and talks reflect this, drawing on expertise from around the world on topics such as measuring and quantifying care, the importance of quality of life, and the future therapeutic and regulatory perspectives. We are delighted to welcome speakers from the US, Australia and Japan to present their experiences. Good care can only be achieved through close partnership between clinicians and patients, and it is a particular pleasure to welcome many representatives of patient organisations from around Europe and the world.

We hope that you will find the conference stimulating and enjoyable.

Dr Janbernd Kirschner
## Agenda

**Thursday 18th April**

### Session 1: Introduction to DMD and DMD Care
Chair: Janbernd Kirschner

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 09:20</td>
<td>Welcome to the conference</td>
<td>Janbernd Kirschner, Universitätsklinikum Freiburg, Veronika Karcagi, Hungarian National Institute of Environmental Health, András Szabó, Semmelweis University</td>
</tr>
<tr>
<td>09:20 - 09:40</td>
<td>Overview of the field of DMD care</td>
<td>Kate Bushby, Newcastle University</td>
</tr>
<tr>
<td>09:40 - 10:00</td>
<td>A global perspective on DMD training activities</td>
<td>Andoni Urtizberea, Hôpital Marin de Hendaye</td>
</tr>
<tr>
<td>10:00 - 10:40</td>
<td>Results of the CARE-NMD questionnaire</td>
<td>Janbernd Kirschner, Universitätsklinikum Freiburg</td>
</tr>
<tr>
<td>10:40 - 11:00</td>
<td>Coffee Break</td>
<td></td>
</tr>
</tbody>
</table>

### Session 2: Evaluating Care for DMD
Chair: Andoni Urtizberea

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 11:30</td>
<td>The CARE-NMD survey in Japan</td>
<td>En Kimura, Japanese National Center of Neurology &amp; Psychiatry</td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td>The Duchenne Connect survey in the USA</td>
<td>Holly Peay, Parent Project Muscular Dystrophy</td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td>The Australian approach to surveying care</td>
<td>Hugh Dawkins, Government of Western Australia</td>
</tr>
<tr>
<td>12:30 - 13:00</td>
<td>Panel discussion/Q&amp;A</td>
<td>All participants</td>
</tr>
<tr>
<td>13:00 - 14:00</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>

### Session 3: Quality of Life in DMD
Chair: Anna Kostera-Pruszcyk

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 14:30</td>
<td>CARE-NMD quality of life questionnaire results</td>
<td>Jes Rahbek, Birgit Steffensen, RehabiliteringsCenter for Muskelsvind</td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td>Living with DMD: patient and family perspectives</td>
<td>Peter Mikkelson, Denmark and Gergely Bujdosó, Hungary</td>
</tr>
<tr>
<td>15:00 - 15:20</td>
<td>The psychology of Duchenne Muscular Dystrophy</td>
<td>Jos Hendriksen, Kempenhaeghe Expertise Centre</td>
</tr>
<tr>
<td>15:20 - 15:40</td>
<td>The role of patient organisations</td>
<td>Elizabeth Vroom, United Parent Project Muscular Dystrophy, Jes Rahbek, RehabiliteringsCenter for Muskelsvind</td>
</tr>
<tr>
<td>15:40 - 16:10</td>
<td>Panel discussion/Q&amp;A</td>
<td>All participants</td>
</tr>
<tr>
<td>16:10 - 16:30</td>
<td>Coffee Break</td>
<td></td>
</tr>
</tbody>
</table>

### Session 4: Current Research: Answering Open Questions in the Care Standards
Chair: Kathi Kinnett

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 - 16:50</td>
<td>Newborn Screening in DMD: Outcomes of the ENMC Workshop</td>
<td>Elizabeth Vroom, United Parent Project Muscular Dystrophy</td>
</tr>
<tr>
<td>16:50 - 17:10</td>
<td>Cardiac Treatment for DMD</td>
<td>John Bourke, Newcastle University</td>
</tr>
<tr>
<td>17:10 - 17:30</td>
<td>Steroid Use: current recommendations and future research</td>
<td>Ulrike Schara, Universitätsklinikum Essen</td>
</tr>
<tr>
<td>17:30 - 17:50</td>
<td>Open issues in the Standards of Care and further developments</td>
<td>Thomas Sejersen, Karolinska Institut</td>
</tr>
<tr>
<td>17:50 - 18:10</td>
<td>Difficulties in the transition from childhood to adulthood</td>
<td>Arpad von Moers, DRK-Kliniken Berlin</td>
</tr>
<tr>
<td>18:10 - 18:30</td>
<td>Panel discussion/Q&amp;A</td>
<td>All participants</td>
</tr>
<tr>
<td>19:30</td>
<td>Dinner</td>
<td></td>
</tr>
</tbody>
</table>
Agenda
Friday 19th April

Session 5: Current Research: Future Therapies and Regulatory Perspectives
Chair: Hanns Lochmüller

08:30 - 09:00  Mutation specific approaches for treatment in DMD
Nathalie Goemans, Université Catholique de Louvain

09:00 - 09:20  Stem cells and gene therapy: hype versus reality
Thomas Voit, Institut de Myologie

09:20 - 09:40  Implementing new treatments in rare diseases: the Pompe experience
Ria Broekgaarden, Vereniging Spierziekten Nederland

09:40 - 10:10  Regulatory perspectives on DMD therapies
Bruno Sepodes, European Medicines Agency

10:10 - 10:40  Panel discussion/Q&A
All participants

10:40 - 11:00  Coffee Break

Session 6: An International Perspective: Networks and the Future of DMD Care
Chair: Monique Ryan

11:00 - 11:30  International networks and DMD registries
Hanns Lochmüller, Newcastle University

11:30 - 11:45  National genetic registries: the Australian experience
Hugh Dawkins, Government of Western Australia

11:45 - 12:00  Care and diagnosis for DMD patients in Hungary
Veronika Karcagi, Hungarian National Institute of Environmental Health

12:00 - 12:30  An EC perspective: Rare Disease Plans, Centres of Expertise, and EUCERD
Georgios Margetidis, European Commission

12:30 - 12:45  The future of DMD care and concluding remarks
Janbernd Kirschner, Universitätspoliklinik Freiburg

12:45 - 14:00  Lunch

Tools & Resources
www.care-nmd.eu/resources

To increase awareness of best-practice care for DMD, and with the kind permission of rights holders, the CARE-NMD project is pleased to highlight a range of resources aimed at medical professionals in a number of languages.

These include:
• Peer reviewed articles including the Standards of Care
• The DMD Family Guide in 27 languages
• A video demonstrating home stretches for DMD
• Training slides based on the consensus Standards of Care
CARE-NMD is an EU funded project (2010-2013) to improve care for Duchenne muscular dystrophy across Europe. It has brought together leading care centres across seven partner countries.

The project has conducted the largest ever survey of DMD care and quality of life, with almost 1,100 respondents. The data gathered will be used to identify areas of strength and weakness in DMD care, in order to improve patient quality of life and life expectancy and reduce health inequalities between and within countries.
Speaker and Chair Biographies

John Bourke
Newcastle University

Dr John Bourke is a Consultant Cardiologist (Electrophysiologist) at the Department of Cardiology, Freeman Hospital, Newcastle upon Tyne, and a Senior Lecturer and Associate Member of the Institute for Genetic Medicine at Newcastle University.

With significant experience in the cardiology of neuromuscular diseases, he is currently leading the DMD Heart Protection Study. This double-blind, randomised, placebo-controlled study across five sites in the United Kingdom will investigate the effect of a combined ACE inhibitor and beta-blocker therapy in preventing the development of cardiomyopathy.

Ria Broekgaarden
Vereniging Spierziekten Nederland

Ria Broekgaarden leads the care department of Spierziekten Nederland, the Dutch Neuromuscular Disease Organization. She is responsible for the Pompe Project and was one of the co-founders and secretary of the International Pompe Association. She was previously a board member of SMA-Europe and the ENMC, and is a board member of the Dutch FSHD Foundation, Stichting FSHD. Ria has participated in various programs aimed at increasing the involvement of patient organisations and researchers from Eastern European countries.

Gergely Bujdosó
Misko Foundation

Gergely Bujdosó represents Misko Foundation, named after his afflicted older son. The organization, being one of the major DMD related charities in Hungary, is a member of Duchenne Alliance, Coalition Duchenne and TREAT-NMD, also being a founding member of the Budapest Neuromuscular Centre. Gergely is a businessman with broad international experience in several for-profit industries.

Kate Bushby
Newcastle University

Professor Kate Bushby is a clinical academic with joint appointments between Newcastle University and the NHS, and was one of the founding coordinators of the TREAT-NMD network. She is Vice President of the EU Committee of Experts on Rare Diseases (EUCERD).

Professor Bushby was lead author of the DMD Care Considerations Working Group, a multidisciplinary panel of 84 experts that developed the international consensus guidelines for DMD. She is also a co-investigator in the FOR-DMD trial to find the optimum regime for corticosteroid use in DMD.

Hugh Dawkins
Government of Western Australia

Professor Hugh Dawkins is the Director of the Office of Population Health Genomics at the Government of Western Australia, and holds adjunct appointments as at the University of Western Australia and Curtin University of Technology. He has over 90 publications across the fields of molecular and cell biology, pathology and infectious disease, and has been instrumental in the development of national rare disease registries in Australia.

Professor Dawkins is Chair of the National Rare Diseases Coordinating Committee, the National Rare Diseases Working Group, and National Neuromuscular Diseases Registry Advisory Group, and is leading Australian efforts in the development of a National Plan for Rare Diseases. He is also the nominated Australian contact for Orphanet and for the International Rare Disease Research Consortium (IRDiRC).

Nathalie Goemans
Universite Catholique de Louvain

Dr Nathalie Goemans is a paediatrician and child neurologist, staff member at the department of Paediatrics and Child Neurology, and Head of the Neuromuscular Reference Center for Children at the University Hospitals Leuven.

She has longstanding experience in clinical research in neuromuscular diseases, and has participated in development and dissemination of international guidelines for diagnosis and treatment of these conditions. She is an investigator in a number of ongoing trials for DMD including PRO051-02: phase 1/2, PRO044: phase 1/2, GSK DMD114044, and PTC124-GD-007-DMD: phase 2b.
Speaker and Chair Biographies

Jos Hendriksen  
Kempenhaeghe Expertise Centre

Dr Jos Hendriksen is a clinical psychologist affiliated with the Epilepsy Centre Kempenhaeghe and the Centre of Neurological Learning Disorders. He participates in research, clinical practice and education and has conducted several scientific studies on learning disorders both generally and in boys with DMD.

He is author of several publications on studies in Attention Deficit Disorders and learning disorders, and has published on DMD and reading, DMD and ADHD, and psychosocial adjustment in DMD. Dr Hendriksen is the co-ordinating teacher in child psychology and childhood neuropsychology at the Maastricht University Medical Centre.

Veronika Karcagi  
Hungarian National Institute of Environmental Health

Dr Veronika Karcagi PhD is Head of Department of Molecular Genetics and Diagnostics at the National Institute of Environmental Health in Budapest. She is the national coordinator of European Molecular Genetics Quality Network for Hungary, and leader of the Hungarian CARE-NMD project team. As the local CARE-NMD partner in Budapest, her team have also led the local organisation of this conference.

En Kimura  
Japanese National Center of Neurology & Psychiatry

Dr En Kimura MD PhD works clinical and translational research for muscular dystrophies. His research interests are in developing molecular therapies for DMD, especially combinations of stem cell and gene therapies.

He currently holds two positions at the National Centre for Neurology and Psychiatry: Chief of the Extra-Early Exploratory Clinical Trial Unit, and Hospital Cluster Ward Chief. He is the Manager and Curator of the Japanese Muscular Dystrophy Registry (Remudy), and a member of the TREAT-NMD Global Database Oversight Committee.

Kathi Kinnett  
Parent Project Muscular Dystrophy

Kathi Kinnett is Vice President for Clinical Care at Parent Project Muscular Dystrophy. A certified paediatric nurse practitioner, she previously worked at Cincinnati Children’s Hospital Medical Centre and was involved in the development of the international consensus guidelines for DMD.

Janbernd Kirschner  
Universitätsklinikum Freiburg

Dr Janbernd Kirschner is the coordinator of the TREAT-NMD Clinical Trial Coordination Centre (CTCC) in Freiburg, Germany and joint coordinator of MD-NET, the German network for neuromuscular disorders. He is head of the neuromuscular laboratory at Freiburg University, and with the CTCC team has established the Care and Trial Site Registry (CTSR) containing feasibility information about neuromuscular centres worldwide.

He is coordinator of the three-year EU-funded CARE-NMD project to improve the quality of care for Duchenne muscular dystrophy, and is involved in the FOR-DMD steroid regime trial.

Anna Kostera-Pruszcyk  
Medical University of Warsaw

Dr Anna Kostera-Pruszcyk is a neuromuscular consultant and the head of the Paediatric Neuromuscular Unit of the Department of Neurology at the Medical University of Warsaw, the CARE-NMD partner in Poland. She has experience in research and implementation of care standards for DMD, and also for myasthenia gravis as a member of the EuroMyasthenia network. Amongst her other appointments, she is on the board of the Polish Paediatric Neurology Society and a member of the Rare Disease Council established by the Polish Ministry of Health.
Speaker and Chair Biographies

Hanns Lochmüller
Newcastle University

Professor Hanns Lochmüller is Chair of Experimental Myology at the Institute of Genetic Medicine, Newcastle University, and was elected Chair of the TREAT-NMD Alliance Executive Committee in April 2012.

He is co-founder and former coordinator of the German muscular dystrophy network (MD-NET), and scientific coordinator of EuroBioBank. He also co-ordinates the RD-Connect project and has led CARE-NMD and TREAT-NMD registry workpackages.

Georgios Margetidis
European Commission

Georgios Margetidis is Senior Scientific Officer at the Executive Agency for Health and Consumers, covering a portfolio of projects under the EU Health Programme including CARE-NMD. He holds a graduate degree in European Law from the Paris I Sorbonne University, and completed postgraduate studies at the Ecole Nationale d’Administration in Paris, France.

Prior to joining the European Commission he held roles at the Greek Ministry of the Interior, Public Administration and Decentralization and Ministry for Health and Social Welfare, where he had project management responsibility for the 2000-2004 Greek National Health Service reform programme.

Peter Mikkelsen
Denmark

Peter Mikkelsen has a BA in Danish literature and media studies, and is a certified systemic coach at senior practitioner level. Since 2005, he has worked as a lecturer and taught Sexology and Disability to medical students. He has recently started working as a coach for people with disabilities, focusing especially on coping mechanisms.

Arpad von Moers
DRK-Kliniken Berlin

Dr Arpad von Moers is the chief physician at the Children’s Hospital of the DRK Clinics Berlin. He is a member of the Executive and Advisory Boards of the Deutschen Gesellschaft für Muskelkranke (DGM) and the Allianz Chronisch Seltenere Erkrankungen (ACHSE).

Holly Peay
Parent Project Muscular Dystrophy

Holly Peay is Vice President for Education and Outreach at Parent Project Muscular Dystrophy and the Director of the DuchenneConnect Registry. Holly trained as a clinical genetic counsellor at the University of South Carolina School of Medicine and is currently enrolled in a PhD program through Leiden University Medical Centre Department of Clinical Genetics. She is an Adjunct Assistant Professor at Johns Hopkins Bloomberg School of Public Health and a Guest Researcher with the National Human Genome Research Institute. In addition to care surveys through the DuchenneConnect Registry, Holly is also studying expectations and therapeutic misconception in Duchenne clinical trials; predictors of participation in clinical research for DBMD; Duchenne treatment preferences and risk tolerance; and predictors of needs and wellbeing among mothers of children with DBMD.

Jes Rahbek
RehabiliteringsCenter for Muskelsvind

Dr Jes Rahbek is a specialist in neuromuscular rehabilitation and also a volunteer in Muskelsvindfonden, the Danish patient organization for NMD. He is also Chairman of the Executive Committee at the European Neuromuscular Centre (ENMC). He works as Chief Medical Officer and Director of the Danish National Rehabilitation Centre for Neuromuscular Diseases.
Speaker and Chair Biographies

Monique Ryan  
Royal Children’s Hospital, Melbourne  

Associate Professor Monique Ryan is a paediatric neurologist with a long interest in clinical research into the neuromuscular disorders of childhood. She is head of the multidisciplinary Neuromuscular Clinic and the Neuromuscular Research Unit at the Royal Children’s Hospital in Melbourne. She has expertise in the design and performance of clinical trials in the field, and is a Clinical Representative on the TREAT-NMD Advisory Committee on Therapeutics (TACT).

Ulrike Schara  
Universitätsklinikum Essen  

Professor Ulrike Schara is a paediatric neurologist at the university hospital in Essen, Germany. She has a long-standing clinical interest in muscle disorders and CMS. She has recently started to build a patient registry for CMS in collaboration with TREAT-NMD.

Thomas Sejersen  
Karolinska Institutet  

Professor Thomas Sejersen is Professor in Neuropediatrics at the Department of Women’s and Children’s Health of Karolinska Institute and consultant paediatrician at the Astrid Lindgrens Barnsjukhus in Stockholm, Sweden. He is a paediatric neurologist with clinical and research interest in neuromuscular disorders.

He has been involved in the development of standards of care for several paediatric neuromuscular disorders as part of the TREAT-NMD network, and is involved in the RARE-bestpractices project to collect, evaluate and disseminate best practice recommendations for rare diseases.

Bruno Sepodes  
European Medicines Agency  

Professor Bruno Sepodes is the Chair of the Committee of Orphan Medicinal Products at the European Medicines Agency.

He is Professor of Pharmacology, Immunopharmacology and Pharmacotherapy at the Faculty of Pharmacy at the University of Lisbon, and has research experience in pharmacology, immunopharmacology and pharmacotoxicology.

Birgit Steffensen  
RehabiliteringsCenter for Muskelvind  

Dr Birgit F. Steffensen is a Senior Researcher at the National Rehabilitation Centre for Neuromuscular Diseases in Denmark. A physiotherapist by training, she has significant experience in the clinical assessment of patients with Neuromuscular Diseases. She has a doctoral degree from Karolinska Institutet in Sweden, and leads the Quality of Life aspects of the CARE-NMD project.

András Szabó  
Semmelweis University  

Professor András Szabó is the Director of the 2nd Department of Paediatrics, Semmelweis University. An expert in paediatric nephrology, his main interests are in bone metabolism and vitamin D. He has significant training experience, and since 1994 has organised an annual international Nephrology Summer School in Budapest. He is a member of the leadership of the Hungarian Society of Nephrology, and also of the Scientific Committee of the Semmelweis University, and has been a board member of the Hungarian Society of Nephrology and Hungarian Society of Pediatricians since 1994.
Speaker and Chair Biographies

Jon Andoni Urtizberea
Hôpital Marin de Hendaye
Dr Jon Andoni Urtizberea is a consultant at the neuromuscular reference centre at Hendaye Hospital in the French Basque region, head of the annual Paris Summer School of Myology, and clinical director for the recently established Russian Spring School of Myology. His special interest is in neuromuscular training, education and international networking. He maintains close links with specialist teams around the world, and with the many graduates of the Summer Schools through an innovative system of telemedicine.

Thomas Voit
Institut de Myologie
Professor Thomas Voit is Professor of Pediatrics, Université Pierre et Marie Curie Paris VI, and Scientific and Medical Director of the Institut de Myologie, Groupe Hospitalier de la Pitié-Salpêtrière, Paris.

Thomas was and is a member of several scientific committees including the Muscular Dystrophy Campaign; Clinical Adviser for Conseil Scientifique, Association Française contre les Myopathies; Institut des Maladies Rares; MRC Centre for Neuromuscular Disease; Dutch Duchenne Parents Project and Integrated Research Centres, German Ministry of Education and Research. He is also a member of the Executive Board for the World Muscle Society.

Elizabeth Vroom
United Parent Projects Muscular Dystrophy (UPPMD)
Dr Elizabeth Vroom is the president of the Dutch Duchenne Parent Project and the chair of the worldwide United Parent Projects Muscular Dystrophy (UPPMD). She is a member of the TREAT-NMD Project Ethics Council as well as the TACT committee and is a practising Orthodontist. Elizabeth is invited to speak at many international conferences about DMD and related issues.

Venue

Hilton Budapest WestEnd
Váci ut 13
1062 Budapest
Hungary

http://www.placeshilton.com/budapest-west-end

The Hilton Budapest WestEnd is located in the heart of Budapest, easily accessible by car, train or underground.

The hotel is only a short walk away from Andrásy Avenue and other major attractions including the Parliament and St Stephen’s Basilica.

Local information

Budapest is the capital and largest city of Hungary. Regarded as one of the most beautiful cities in Europe, its extensive World Heritage Site includes the banks of the Danube, the Buda Castle Quarter, Andrásy Avenue, Heroes’ Square and the Millennium Underground Railway, the second oldest in the world. Further information about the Budapest area is available at http://www.budapest.com

The currency is Hungarian Forint (HUF), which is currently approximately 300:1 to the Euro. For up-to-date exchange rates, see http://www.xe.com;

Road maps of Budapest and the surrounding area are available at http://maps.google.com

Local weather conditions are available at http://weather.yahoo.com
Sights

The Royal Palace is located at the top of Castle Hill in the picturesque Castle District of Buda. The Castle has a mixture of architectural styles, ranging from Gothic to Baroque. Today it is the country’s most important cultural centre housing numerous museums and the majority of the buildings are historical monuments. The Budapest History Museum contains an exhibition explaining the history of the city as well as archaeological remains of the palace. Also within the palace complex are the Hungarian National Gallery, the National Library and the Ludwig Museum.

Fisherman’s Bastion was built in 1905 on the medieval castle walls, the neo-Romanesque ramparts named after the fishermen whose duty it was to defend this side of the hill during the Middle Ages.


The Chain Bridge was the first stone bridge to be built over the Danube and is the most famous with its lion statues. Today nine bridges span the river linking Buda to Pest, but the Chain Bridge remains pride of place as the symbol of the city, a magnificent sight when floodlit at night.

On the bank of the Danube stands the Parliament Building, seat of the National Assembly of Hungary. In Gothic Revival style, it is an imposing sight and prominent feature of the city’s panorama. With its red dome, white stone lace ornamentation and spires, it is the city’s most decorative structure.

Tourist information is available at http://www.budapest.com/city_guide/attractions.en.html, while the free flyer “FunZine” provides current event information and is available at the airport or at http://www.funzine.hu.

Restaurants

Sir Lancelot Knights’ Restaurant
Podmaniczky str. 14 (5 min walk from Hilton WestEnd)
H-1065 Budapest

Busulo Juhasz
Gellért-hegy
Kelenhegyi street 58
1118 Budapest

Onyx – Gerbeaud (Michelin star)
Vörösmarty tér 7-8
1051 Budapest
http://www.gerbeaud.hu

Firkász Restaurant (within walking distance)
Tátra street 18
District XIII
Budapest
http://www.firkasz.hu

The Liszt Ferenc Square, within walking distance of the hotel, has several restaurants and bars.
Getting to Budapest

By plane

Budapest Franz Liszt International Airport has three terminals

• Terminal 1 (Ferihegy 1, mainly used for low-budget airlines)
• Terminal 2A and Terminal 2B (Ferihegy 2)

Budapest Ferihegy International Airport is located 16 km from the city centre. Flight schedules and further information about the airport is available at http://www.bud.hu/english

To and from the airport

Train

Hungarian State Railways (MAV) run suburban and long-distance services between Terminal 1 and Budapest-Nyugati Railway Station, a couple of minutes from Hilton WestEnd. The journey takes approximately 25 minutes, with single tickets approximately 370HUF/1.25. A connection between Terminals 2A/2B and the station at Terminal 1 is provided by Bus (200E) every 10 minutes for an additional fee of 350-450HUF.

Minibus Shuttle

The airport offers a city-wide “shared ride” shuttle van service between any apartment, hotel, office or residence and Ferihegy International Airport, combining the comfort of taxis with reasonable rates. Tickets can be purchased in the arrival hall and at the Airport Passenger Service counters near the Airport exits. A single ticket costs approximately EUR 10.

By bus and underground

Airport Buses (39 and 200E) depart from the Airport every 10 minutes, providing connection to the City Center and Budapest’s metro at the Kobánya-Kispest Metro Station. The ‘Blue’ metro (line 3) takes 25 minutes to reach Budapest-Nyugati Station. For information and prices on public transportation in Budapest see http://www.bkv.hu/en.

An alternative to single tickets, the Budapest Card provides free public transport and discounted entry to attractions. Further information is available at http://budapest-card.com/en

Taxi

Taxis are available from the taxi stands at the airport or throughout the city, and rates are indicated on the meter. The fares from Budapest Ferihegy Airport to the city centre can reach 4500-5500 HUF (cc. EUR 15-20) and the journey takes around 15 to 20 minutes.

Not all taxis accept credit cards: if you need a taxi that does, call ahead of time to reserve one.

The Hilton WestEnd recommends the following taxi operators:
City Taxi: +36 1 2 111 111 / +36 20 2 111 111

Taxi 4: +36 1 4 444 444

The Hilton Budapest WestEnd is located in the heart of Budapest, easily accessible by car, train or underground.
CARE-NMD is co-funded by the European Union under grant number 20091205.

Although every effort has been made to ensure that the details in this brochure are correct, the organisers cannot accept any responsibility for errors, omissions, or changes to the programme.